Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medtronic PLC (MDT) vs Sanofi SA (SNY) Price & Performance

Medtronic PLCTrade

Price performance (Past 24H)

Key statistics

Medtronic PLC vs Sanofi SA — how do they compare? Medtronic PLC trades at $90.72 (market cap $116.07B), while Sanofi SA trades at $43.62 (market cap $104.30B). The key difference: Medtronic PLC and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.

MDTSNY
Market Cap
$116.07B$104.30B
Sector
HealthHealth
52-Week High
$105.35$52.34
52-Week Low
$73.75$41.33
Enterprise Value
$134.82B$124.19B
Dividend Yield
3.18%5.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medtronic PLC

Medtronic (MDT) trades at $89.99, up 0.65% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, 13.2% net income margin, and positive cash flow trends. Recent product innovations including the Hugo robotic surgery platform and AI surgical tools position MDT for growth. Analyst consensus remains strongly positive with 60% buy ratings and $98.75 price target.

MDT presents a compelling investment case with steady revenue growth, dividend aristocrat status, and technological leadership in medical devices. Key risks include increasing debt levels and competitive pressures from Intuitive Surgical. The stock's current valuation at 24.31 P/E appears reasonable given growth prospects, with upside potential to consensus targets if execution continues.

Sanofi SA

SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.

Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Medtronic PLC

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Read more on MDT

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY